Homocysteine Blood Levels and Mandatory Folic Acid Fortification in Serbia

Overview

Journal Curr Pharm Des

Publisher Bentham Science Publishers

Date 2024 Oct 4

PMID 39364862

Authors

Zorana Vasiljevic

Natasa Zlatic

Dubravka Rajic

Predrag Mitrovic

Mihajlo Viduljevic

Dragan Matic

Milika Asanin

Sanja Stankovic

Affiliations

Soon will be listed here.

Abstract

Introduction: The current study aims to investigate the blood Hcy levels in patients with CAD and hypertension in Serbia, a country with a high incidence and mortality of both diseases.

Methods: The level of Hcy in the Serbian population was assessed in 123 patients with chronic coronary artery disease (CAD) and hypertension. There were 53 patients with chronic CAD and 70 patients with hypertension (HTA), but without CAD.

Results: The Hcy levels were high in both groups of patients (the mean Hcy level of 16.0 ± 7.0 μmol/L) without a statistical difference between the patients in the CAD (14.9 ± 7.3 μmol/L) and hypertension (16.7 ± 6.7 μmol/L) groups. Hypercholesterolemia was found in 81% of the patients with CAD and 92.0% of the patients with HTA, as a common concern across both clinical conditions. It was also found that not a single conventional risk factor (diabetes, hypertension, the smoking status, the family history of CAD, and hyperlipidemia) may individually influence Hcy levels. By contrast, the low levels of vitamin B12 may be related to the high levels of Hcy.

Conclusion: Given the fact that it is known that various factors interact and influence Hcy levels and associated cardiovascular risks, specific dietary habits, lifestyle and the other Serbia-specific possible factors were done.

References

Lonn E, Yusuf S, Arnold M, Sheridan P, Pogue J, Micks M . Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006; 354(15):1567-77. DOI: 10.1056/NEJMoa060900. View

Chrysant S, Chrysant G . The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. Expert Rev Cardiovasc Ther. 2018; 16(8):559-565. DOI: 10.1080/14779072.2018.1497974. View

Djuric D, Jakovljevic V, Rasic-Markovic A, Djuric A, Stanojlovic O . Homocysteine, folic acid and coronary artery disease: possible impact on prognosis and therapy. Indian J Chest Dis Allied Sci. 2008; 50(1):39-48. View

Foscolou A, Rallidis L, Tsirebolos G, Critselis E, Katsimardos A, Drosatos A . The association between homocysteine levels, Mediterranean diet and cardiovascular disease: a case-control study. Int J Food Sci Nutr. 2018; 70(5):603-611. DOI: 10.1080/09637486.2018.1547688. View

Wald D, Law M, Morris J . Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002; 325(7374):1202. PMC: 135491. DOI: 10.1136/bmj.325.7374.1202. View

Debreceni B, Debreceni L . Why do homocysteine-lowering B vitamin and antioxidant E vitamin supplementations appear to be ineffective in the prevention of cardiovascular diseases?. Cardiovasc Ther. 2011; 30(4):227-33. DOI: 10.1111/j.1755-5922.2011.00266.x. View

Abraham J, Cho L . The homocysteine hypothesis: still relevant to the prevention and treatment of cardiovascular disease?. Cleve Clin J Med. 2010; 77(12):911-8. DOI: 10.3949/ccjm.77a.10036. View

Peng H, Man C, Xu J, Fan Y . Elevated homocysteine levels and risk of cardiovascular and all-cause mortality: a meta-analysis of prospective studies. J Zhejiang Univ Sci B. 2015; 16(1):78-86. PMC: 4288948. DOI: 10.1631/jzus.B1400183. View

Garcia-Fernandez E, Rico-Cabanas L, Rosgaard N, Estruch R, Bach-Faig A . Mediterranean diet and cardiodiabesity: a review. Nutrients. 2014; 6(9):3474-500. PMC: 4179172. DOI: 10.3390/nu6093474. View

10.

Lewis S, Ebrahim S, Davey Smith G . Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate?. BMJ. 2005; 331(7524):1053. PMC: 1283183. DOI: 10.1136/bmj.38611.658947.55. View

11.

. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002; 288(16):2015-22. DOI: 10.1001/jama.288.16.2015. View

12.

Refsum H, Nurk E, Smith A, Ueland P, Gjesdal C, Bjelland I . The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr. 2006; 136(6 Suppl):1731S-1740S. DOI: 10.1093/jn/136.6.1731S. View

13.

Iso H, Moriyama Y, Sato S, Kitamura A, Tanigawa T, Yamagishi K . Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation. 2004; 109(22):2766-72. DOI: 10.1161/01.CIR.0000131942.77635.2D. View

14.

Menotti A, Puddu P, Maiani G, Catasta G . Cardiovascular and other causes of death as a function of lifestyle habits in a quasi extinct middle-aged male population. A 50-year follow-up study. Int J Cardiol. 2016; 210:173-8. DOI: 10.1016/j.ijcard.2016.02.115. View

15.

Bostom A, Rosenberg I, Silbershatz H, Jacques P, Selhub J, DAgostino R . Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med. 1999; 131(5):352-5. DOI: 10.7326/0003-4819-131-5-199909070-00006. View

16.

Zhang Z, Gu X, Fang X, Tang Z, Guan S, Liu H . Homocysteine and the Risk of Cardiovascular Events and All-Cause Death in Elderly Population: A Community-Based Prospective Cohort Study. Ther Clin Risk Manag. 2020; 16:471-481. PMC: 7250705. DOI: 10.2147/TCRM.S239496. View

17.

Bots M, Launer L, Lindemans J, Hoes A, Hofman A, Witteman J . Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med. 1999; 159(1):38-44. DOI: 10.1001/archinte.159.1.38. View

18.

Anderson J, Muhlestein J, Horne B, Carlquist J, Bair T, Madsen T . Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation. 2000; 102(11):1227-32. DOI: 10.1161/01.cir.102.11.1227. View

19.

Barnabe A, Alessio A, Bittar L, Mazetto B, Bicudo A, de Paula E . Folate, vitamin B12 and Homocysteine status in the post-folic acid fortification era in different subgroups of the Brazilian population attended to at a public health care center. Nutr J. 2015; 14:19. PMC: 4354994. DOI: 10.1186/s12937-015-0006-3. View

20.

Roth G, Mensah G, Johnson C, Addolorato G, Ammirati E, Baddour L . Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; 76(25):2982-3021. PMC: 7755038. DOI: 10.1016/j.jacc.2020.11.010. View